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Received March 11, 2013; accepted August 28, 2013AbstractBackground: Photodynamic therapy (PDT) has previously been reported to be effective in treating polypoidal choroidal vasculopathy (PCV),
with satisfactory polyp regression. However, the optimum treatment protocol remains controversial. This study compared the effect of reduced-
fluence PDT combined with intravitreal bevacizumab (rPDT/IVB) and standard-fluence PDT (sPDT) alone for treating symptomatic PCV in
Chinese patients.
Methods: A retrospective review was carried out of the medical records of patients with PCV who were treated with rPDT/IVB (14 eyes of 13
patients) or sPDT (12 eyes of 12 patients) with at least 6 months of follow-up.
Results: The mean best-corrected visual acuity of the rPDT/IVB group improved significantly at the 6-month follow-up (p ¼ 0.041). Only one
eye (7.1%) in the rPDT/IVB group showed a decrease in visual acuity, compared with four eyes (33.3%) in the sPDT group. A total of 40.0% of
eyes in the sPDT group showed increased lipid exudate at follow-up 1 month after treatment, whereas no increase in lipid exudate was observed
in the rPDT/IVB group (p ¼ 0.015). The mean maximum area of post-treatment hemorrhage in the rPDT/IVB group was smaller than that in the
sPDT group (2.57  2.74 mm2 vs. 12.69  10.28 mm2, p ¼ 0.042).
Conclusion: Combination therapy with rPDT/IVB for patients with PCV showed encouraging results in vision improvement, a lower decrease in
visual acuity, significantly less post-treatment lipid exudate and a smaller area of post-treatment hemorrhage at the 6-month follow-up than
patients treated with sPDT.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Polypoidal choroidal vasculopathy (PCV) has a distinctive
choroidal appearance characterized by an abnormal vascular
network terminating in polypoidal structures. The disease isThe authors declare that there are no conflicts of interest related to the subject
matter or materials discussed in this article.
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http://dx.doi.org/10.1016/j.jcma.2013.10.012more prevalent in Asian populations, with an incidence
ranging from 22.3% to 40%, compared with a reported inci-
dence of 4e13.9% in Caucasian patients diagnosed with
presumed age-related macular degeneration (AMD).1e5
Polypoidal choroidal vasculopathy often follows a remit-
tingerelapsing course associated with subretinal hemorrhage,
macular edema and retinal pigment epithelial (RPE) detach-
ment. Although the natural course of PCV is reported to be
more favorable than exudative AMD, about 35% to 50% of
patients develop a loss of vision due to recurrent bleeding or
leakage and RPE atrophy after a longer follow-up period.1,2,6hinese Medical Association. All rights reserved.
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Several studies have shown encouraging results with standard-
fluence photodynamic therapy (sPDT) with verteporfin (50 J/
cm2 delivered as 600 mWover 83 seconds) in the regression of
the polypoidal lesions (85e95%) and vision stabilization or
improvement (80.9e95%) at the 1-year follow-up.3,7,8 How-
ever, some studies have shown that sPDT damages the phys-
iological choriocapillary layer beyond the irradiated area and
that repeat sPDT results in persistent choriocapillary non-
perfusion and can lead to a decrease in vision.9e11 The
vascular endothelial growth factor (VEGF) surge secondary to
choriocapillary ischemia may be related to the recanalization
of choriocapillaries, which may lead to post-treatment retinal
hemorrhage in PCV.12,13 Furthermore, 19% to 30.8% of pa-
tients with PCV experienced retinal hemorrhage or even
massive subretinal hemorrhage and vitreous hemorrhage after
sPDT.3,7,14e17 Several studies have shown that the reduced-
fluence PDT (rPDT, 25 J/cm2 delivered as 600 mW over 42
seconds or 300 mW over 83 seconds) resulted in less chorio-
capillary nonperfusion than sPDT,18,19 with a similar choroidal
neovascularization closure rate.20 Yamashita et al21 reported 1-
year results of rPDT on patients with PCV and showed
improved visual outcome and fewer treatment sessions
compared with the results of sPDT from other studies.22,23
Intravitreal injection of an anti-VFGF agent is found to
reduce exudation in the eyes of patients with PCV, but has a
limited effect on the regression of polypoidal lesions.24,25 The
combination therapy of sPDT and intravitreal anti-VEGF in-
jection into the eyes of patients with PCV was found to reduce
the incidence of post-treatment subretinal hemorrhage,
resulting in a better visual outcome with a similar polyp
regression rate to sPDT monotherapy.13 A recent study of
Chinese patients showed that the treatment effect of PDT
combined with intravitreal bevacizumab injection was supe-
rior to PDT monotherapy within 1 year of follow-up.26
Theoretically, the combination of rPDT, which has a reduced
extent of physiological choriocapillary closure, and the anti-
VEGF, which has both antiangiogenic and antipermeability
effects, may result in less post-treatment exudation and hem-
orrhage, and reduced additional vision loss due to chorioca-
pillary and RPE degeneration. The purpose of this study was to
investigate the efficacy and safety of rPDT combined with
intravitreal bevacizumab injection (IVB) and sPDT mono-
therapy in Chinese patients with symptomatic PCV.
2. Methods
This retrospective comparative case series included patients
with symptomatic PCV treated with sPDTmonotherapy or rPDT
and IVB (rPDT/IVB) at Taipei Veterans General Hospital,
Taiwan from June 2002 to August 2008. The diagnosis of PCV
was based on the presence of characteristic aneurysmal poly-
poidal lesions with a branching network of choroidal vessels
observed in indocyanine angiography (ICGA). The criteria for
enrollmentwere: (1) an absence of evidence suggesting choroidal
neovascularization associated with AMD, pathological myopia,
idiopathic choroidal neovascularization, presumed ocularhistoplasmosis, angioid streak, and other secondary choroidal
neovascularization; (2) the absence of other maculopathies, such
as diabetic maculopathy; (3) no previous retinal surgery within
the last 6 months; (4) no previous PDT treatment within 1 year;
and (5) a completed 6-month follow-up after treatment. The
Institutional Review Board for Human Research of Taipei Vet-
erans General Hospital approved this study. Informed consent
was obtained from each of the participants.
All patients received a comprehensive ocular examination
including best-corrected visual acuity (BCVA), intraocular
pressure measurement, indirect ophthalmoscopy, slit-lamp
biomicroscopy with noncontact lens, color fundus photog-
raphy before treatment (baseline), and at months 1 and 3 and
then at 3-month intervals after treatment. The BCVA was
measured with the standard Snellen chart at 6 m. To quantify
the visual changes, all Snellen BCVAs were converted to a
logarithm of the minimum angle of resolution (logMAR)
BCVA. Vision tested with counting fingers was assigned with
logMAR 2.0. An increase in BCVA of more than two lines
(logMAR BCVA change 2 lines) was considered an
improvement, and a decrease of more than two lines was
considered a worsening. The ICGA and/or fluorescein angi-
ography (FA) were evaluated at baseline and at 3-month in-
tervals after treatment. The ICGA was performed with a
scanning laser ophthalmoscope (HRA2, Heidelberg Engi-
neering, Heidelberg, Germany) and fundus photography and
FA were taken by a digital fundus camera (Canon CF-60UD,
Tokyo, Japan) at a 60 view. The presence of hemorrhage
and lipid exudate was documented by fundus photography.
Photodynamic therapy with verteporfin (Novartis, Basel,
Switzerland) was performed with 6 mg per square meter of
body surface area via an intravenous infusion of 30 mL over
10 minutes. Five minutes after complete infusion, the patients
received an irradiance of 600 mW/cm2 with a laser light at
689 nm delivered over 42 seconds (reduced-fluence) or 83
seconds (standard-fluence). The intravitreal bevacizumab in-
jection was performed in an operating room under sterile
conditions. For the patients who received rPDT before the
injection, the light was dimmed to avoid further photo-
activation of verteporfin. Topical anesthesia with 0.5% prop-
aracrine hydrochloride was applied three times before
disinfection of the ocular surface and periocular skin with a
5% povidoneeiodine solution. Bevacizumab (0.1 mL, 2.5 mg)
(Avastin, Roche, Basel, Switzerland) was injected through the
inferior pars plana into the vitreous cavity using a 30-gauge
needle. Anterior chamber paracentesis was performed before
the injection to avoid an intraocular pressure spike. A topical
antibiotic was prescribed as prophylaxis against infection. The
treatment choice of rPDT/IVB or sPDT was based on the
discretion of the retinal specialists (L.I.L., S.J.C., F.L.L.,
Y.C.S.). Repeat treatments were administered every 3 months
to the eyes of patients with either persistent or new hyper-
fluorescence on ICGA or the presence of leakage on FA
suggesting an active lesion. Additional IVB was given during
the follow-up period between the 3-month treatment interval
of PDT when optical coherent tomography demonstrated
cystoid macular edema and/or subretinal fluid.
Table 1









Male (n, %) 10 (76.9) 8 (66.7)
Female (n, %) 3 (23.1) 4 (33.3)
Age (y, mean  SD) 72.6  10.4 67.1  9.0 0.327c
Baseline BCVA
(logMAR, mean  SD)




0.63  0.49 0.65  0.38 0.734c
Presence of hemorrhage
at baseline (n, %)
7 (50.0) 7 (58.3) 0.671b
Presence of lipids at
baseline (n, %)
12 (85.7) 8 (66.7) 0.250b
No. of PDT treatment
sessionsa (mean  SD)
1.4  0.5 1.4  0.5 0.760c
Spot size of PDT (mm,
mean  SD)
2749.8  1105.9 3613.3  1296.7 0.085c
Follow-up time (mo,
mean  SD)
10.3  3.8 11.0  4.1 0.756c
BCVA ¼ best-corrected visual acuity; rPDT/IVB ¼ reduced-fluence photo-
dynamic therapy and intravitreal bevacizumab injection; sPDT ¼ standard-
fluence photodynamic therapy.
a PDT treatment sessions within the 6-month follow-up.
b Pearson chi-square test.
c ManneWhitney test.
Fig. 1. Changes in the mean logarithm of the minimum angle of resolution
(LogMAR) best-corrected visual acuity (BCVA) of the two groups at the 6-
month follow-up. In the reduced-fluence photodynamic therapy and intra-
vitreal injection of bevacizumab (rPDT/IVB) group, the mean BCVA at the 6-
month follow-up was significantly better than the mean BCVA at baseline (*
p ¼ 0.041, Wilcoxon signed rank test). sPDT ¼ standard-fluence photody-
namic therapy.
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months with the mean BCVA at baseline of the two groups.
Secondary outcomes included the proportion of eyes in the
respective group that had improved (2 lines), stable (1
line), or decreased (2 lines) vision at 6 months compared
with the baseline BCVA, comparison of the mean BCVA of
the two groups at the 6-month follow-up, and the PCV
regression rate of the two groups at the 6-month follow-up.
The ocular and systemic complications of the treatment
were also recorded and analyzed. The changes in lipid exudate
of the two groups of patients after treatment were evaluated
through fundus photography. Hemorrhagic complication was
defined as new hemorrhage or increased hemorrhage after
treatment. The area of retinal hemorrhage documented by
fundus photography was measured using an industrial
computer-aided design software package (GstarICAD 2008
Professional Beijing, China). The measured area was con-
verted to the actual size on the retina in proportion to the
magnification of the camera and the software for statistical
analysis. The initial size of hemorrhage was defined as the area
of new hemorrhage documented after treatment, and the
maximum size of hemorrhage was defined as the largest area
of hemorrhage documented throughout the follow-up period.
Statistical analysis was performed with SPSS for Windows,
Version 15.0 (SPSS Inc., Chicago, IL, USA). The baseline
characteristics were analyzed using nonparametric tests for
continuous variables and the c2 test for categorical variables.
The changes in BCVA at 1-month, 3-month and 6-month in-
tervals in each group were analyzed using the Wilcoxon
signed rank test. The ManneWhitney test was used to
compare the post-treatment hemorrhage areas between the two
groups. All values were presented as mean  SD for contin-
uous variables and as a percentage for categorical variables. A
value of p < 0.05 was considered statistically significant.
3. Results
During the study period, 57 patients with symptomatic PCV
confirmed by ICGA received PDT. A total of 32 patients was
excluded: 12 had concomitant intravitreal triamcinolone in-
jection, seven received rPDT without IVB, five received sPDT
and additional IVB during the follow-up period, four received
PDT within 1 year or retinal surgery within 6 months before
starting the PDT treatment, and four had incomplete medical
records and were lost in follow-up. Twenty-five Chinese pa-
tients with 26 eligible eyes were therefore included in this
study. Fourteen eyes from 13 patients received rPDT/IVB, and
12 eyes from 12 patients received sPDT monotherapy. Table 1
shows the demographic and clinical data. In the rPDT/IVB
group, IVB was performed after rPDT on the same day in all
patients except one, who received rPDT within seven days
after IVB. There was no difference in the mean PDT treatment
session between the two groups within the 6-month follow-up
period. Five eyes (35.7%) in the rPDT/IVB group and five
eyes (41.7%) in the sPDT group required two treatment epi-
sodes. All patients in the rPDT/IVB group underwent IVB
along with each rPDT session, except for four eyes thatreceived additional IVB within 6 months. No patient in the
sPDT group received IVB during the follow-up period. The
mean BCVA of the rPDT/IVB group at the 6-month follow-up
was significantly better than the baseline mean BCVA
( p ¼ 0.041, Wilcoxon signed rank test), whereas there was no
significant change in the mean BCVA of the sPDT group at the
6-month follow-up (Fig. 1). Although there was no difference
Fig. 2. Changes in the best-corrected visual acuity (BCVA) in patients with
polypoidal choroidal vasculopathy treated with reduced-fluence photodynamic
therapy combined with intravitreal bevacizumab injection (rPDT/IVB) or
standard-fluence photodynamic therapy alone (sPDT) at the 6-month follow-
up.
Fig. 3. Changes in lipid exudate at 1 month, 3 months and 6 months post-
treatment for the two groups. There was a significant increase in lipid
exudate in the standard-fluence photodynamic therapy (sPDT) group
compared with the reduced-fluence photodynamic therapy and intravitreal
injection of bevacizumab (rPDT/IVB) group at 1 month after treatment
(p ¼ 0.015, c2 test).
Table 2








New hemorrhage (n, %) 5 (35.7) 7 (58.3) 0.249a
Initial size
(mm2, mean  SD)
0.87  0.95 8.33  10.26 0.062b
Maximum size
(mm2, mean  SD)





<1 mo (n, %) 5 (100.0) 6 (85.7)
1e3 mo (n, %) 0 (0.0) 1 (14.3)
rPDT/IVB ¼ reduced-fluence photodynamic therapy and intravitreal bev-
acizumab injection; sPDT ¼ standard-fluence photodynamic therapy.
a Pearson chi-square test.
b ManneWhitney test.
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between the two groups (Table 1), it is worth noting that
only one eye (7.1%) in the rPDT/IVB group suffered a
decrease in vision compared with four eyes (33.3%) in the
sPDT group (Fig. 2).
Twelve eyes in the rPDT/IVB group had an ICGA exami-
nation at the 6-month follow-up. Seven eyes (58.3%) had a
regressed polypoidal lesion and five eyes (41.7%) had
persistent polyps. In the sPDT group, seven eyes (58.3%) had
an ICGA examination at the 6-month follow-up. Three eyes
(42.9%) showed polyp regression and four eyes (57.1%)
showed a persistence of polyps. A branching vascular network
persisted in all eyes at the 6-month follow-up.
Fig. 3 shows the change in lipid exudate after treatment. None
of the eyes in the rPDT/IVB group showed increased lipid
exudate throughout the follow-up period,whereas 40.0%of eyes
in the sPDT group had an increased lipid exudate at the 1-month
follow-up (p ¼ 0.015, c2 test). Five eyes (35.7%) in the rPDT/
IVB group experienced post-treatment retinal hemorrhage, and
all occurred within 1 month of treatment. In the sPDT group,
seven eyes (58.3%) had retinal hemorrhage and six (85.7%) of
these developed within 1 month of treatment. All the post-
treatment retinal hemorrhages were located adjacent to or
within the PCV lesion. The mean maximum size of retinal
hemorrhage in the rPDT/IVB group was significantly smaller
than that of the sPDT group (Table 2, Figs. 4 and 5). Two eyes in
the sPDT group underwent intravitreal injection of tissue plas-
minogen activator and gas tamponade to displace the sub-
macular hemorrhage. No other ocular complications, such as
endophthalmitis and intraocular pressure elevation, or any sys-
temic adverse event was noted during the follow-up period.
4. Discussion
Photodynamic therapy with standard-fluence has been re-
ported to have a satisfactory effect in the treatment of PCV,
Fig. 4. An 85-year-old man reported blurred vision (20/63) of the left eye for 2 months. (A) Fundoscopic examination showed parafoveal reddish orange nodules
with subretinal fluids and subretinal pigment epithelial hemorrhage. (B) Indocyanine green angiography showed a branching vascular network with polypoidal
lesions. Reduced-fluence photodynamic therapy with a 1600 mm irradiation spot combined with intravitreal injection of bevacizumab (2.5 mg) was performed. (C)
Two weeks after treatment, a new subretinal hemorrhage evolved (0.26 mm2) and his visual acuity decreased to 20/200. (D) Three months later, the subretinal
hemorrhage was absorbed. The visual acuity was 20/63 and subsequently improved to 20/32 at the 6-month follow-up.
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bilization or improvement at the 1-year follow-up.3,7,8 How-
ever, some patients have experienced extensive subretinal
hemorrhage after PDT, which has compromised their visual
acuity.3,8 In our study, patients in the rPDT/IVB group had an
improved BCVA at the 6-month follow-up, less lipid exudate
and a smaller area of retinal hemorrhage after treatment than
patients in the sPDT group.
There was no significant improvement in the mean BCVA
at the 6-month follow-up in the sPDT group, which was
comparable with the results of Akaza et al,22 whereas eyes in
the rPDT/IVB group had a significantly better mean BCVA at
the 6-month follow-up compared with the mean BCVA at
baseline. Moreover, the proportion of eyes having a decrease
in vision was also lower in the rPDT/IVB group than in the
sPDT group. Similarly, in a study of sPDT combined with
ranibizumab for PCV,13 the mean change in BCVA throughout
the study period was significantly better than the contempo-
rary studies of sPDT on PCV.3,7,8,22,23,27 Sato et al28 also re-
ported a significant improvement in BCVA at the 6emonth
follow-up in a series of patients with PCV treated with
sPDT and IVB. A study using rPDT and intravitreal ranibi-
zumab also reported significant BCVA improvement at the 1-
year follow-up.29
The better visual outcome of patients with PCV receiving
the combination therapy of PDT and anti-VEGF may be
related to the antipermeability effect of anti-VEGF, which can
emolliate the vascular hyperpermeability and extravasation
after PDT.30,31 In our study, none of the eyes in the rPDT/IVBgroup showed increased lipid exudates throughout the follow-
up period, which is a prominent sign of vascular leakage,32
whereas 40% of eyes in the sPDT group had increased lipid
exudate in the 1st month after treatment. However, intravitreal
bevacizumab injection alone may not play a significant part in
preventing a long-term decrease in vision after standard-
fluence PDT. A recent study compared the treatment effect
of standard-fluence PDTwith or without IVB, and showed that
the percentage of patients with three or more lines decrease in
visual acuity was similar between the two groups (11.1% vs.
12.1%) at the 1-year follow-up.26 It is postulated that less RPE
damage associated with less choroidal ischemia after rPDT
may play a part in a smaller decrease in vision after treat-
ment.18,20,21 Yamashita et al21 reported that 57% of eyes with
PCV that received rPDT had mild to moderate choroidal
nonperfusion at 1 week, and 96% recovered to the pretreat-
ment status at the 3-month follow-up. Our study showed that
fewer eyes in the rPDT/IVB group experienced more than two
lines decrease in visual acuity compared with those in the
sPDT group.
Recent studies have shown that extensive subretinal hem-
orrhage may occur after sPDT.3,7,14e17 In our study, post-
treatment retinal hemorrhage was less severe in the rPDT/
IVB group, with smaller initial and maximum areas of hem-
orrhage than the sPDT group. It was postulated that the oc-
clusion of the choroidal vessels and PCV lesions resulting
from PDT, followed by reperfusion (or recanalization), caused
this detrimental hemorrhagic complication.14,16 Several
studies have documented significant vascular occlusion9,33,34
Fig. 5. An 81-year-old man reported blurred vision of the left eye (20/63) for 3 months. (A) Fundoscopic examination showed subretinal hemorrhage, pigment
epithelial detachment, subretinal fluid and a reddish-orange nodule. (B) Indocyanine green angiography showed a branching vascular network with polypoidal
lesions. Standard-fluence photodynamic therapy (sPDT) was performed with a 4800 mm irradiation spot. (C) Two months after treatment, fundoscopic examination
showed increased subretinal hemorrhage with hemorrhagic pigment epithelial detachment. Visual acuity of the left eye was 20/200. (D) Indocyanine green
angiography showed two prominent polypoidal lesions. Intravitreal injection of tissue plasminogen activator and gas tamponade was performed to displace the
hemorrhage. (E) Two weeks after the operation, the blood at the fovea was displaced. sPDTwas performed again with a 4100 mm irradiation spot. (F) Three months
after the second PDT, fundoscopic examination showed retinal pigment epithelium atrophy and a glial scar. The visual acuity remained 20/200 in the left eye.
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use of rPDT/IVB, both the choroidal nonperfusion and the
VEGF surge can be reduced, which results in less severe post-
treatment hemorrhage.21,26,29,35
The limitations of our study include a small sample size
and short follow-up period, which is in part due to the relative
rarity of eligible patients with PCV; the diagnosis was newly
established during the study period and a diversity of treatment
options was given at that time before a consensus evolved.
Exudation after treatment was documented semiquantitatively
by changes in lipid exudate on fundus photographs and not
quantitatively by optical coherent tomography. Choroidal
vascular change after PDT was not documented in this study.
Despite these limitations, our study has shown that patients
who received rPDT/IVB had improved BCVA at the 6-month
follow-up, a smaller decrease in visual acuity, and had less
post-treatment hemorrhage and exudate than those whoreceived sPDT monotherapy. Further large prospective ran-
domized studies with long-term follow-up are warranted to
establish the optimum treatment for PCV.
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